• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechTheranos

Jury begins deliberations in fraud trial of Theranos CEO Elizabeth Holmes

By
Joel Rosenblatt
Joel Rosenblatt
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Joel Rosenblatt
Joel Rosenblatt
and
Bloomberg
Bloomberg
Down Arrow Button Icon
December 17, 2021, 7:00 PM ET

After three months and dozens of witnesses, Elizabeth Holmes’s fate will be decided by 12 jurors.

Closing arguments concluded Friday in the Theranos founder’s criminal fraud trial in San Jose, California. After receiving instructions from the judge, the jury can begin deliberations. 

The jury must decide whether the 37-year-old entrepreneur is guilty of fraud and conspiracy charges filed in 2018, the same year that her blood-testing startup collapsed after previously reaching a valuation of $9 billion. Holmes is facing a maximum sentence of 20 years in prison if convicted.

Throughout the trial, prosecutors have portrayed Holmes as grossly exaggerating the capabilities and reliability of Theranos testing machines she pitched as revolutionary. Jurors also heard from several Theranos employees that the company’s lab took dangerous shortcuts to conceal shortcomings with the analyzers, and from patients who recounted receiving inaccurate test results that left them anxious about their health.

Holmes spent seven days on the witness stand testifying in her own defense. She alternated between deflecting blame, failing to remember certain events and accepting responsibility for mistakes, even while insisting she didn’t intend to deceive anyone. 

During closing arguments, Assistant U.S. Attorney Jeff Schenk told the jury on Thursday that when Theranos was running out of money — around 2013 and 2014 — Holmes “made the decision to defraud her investors and then to defraud patients.” 

“She chose fraud over business failure,” Schenk said.

If Holmes had been honest about Theranos and its prospects, she wouldn’t have told investors that the company’s technology was endorsed by big pharmaceutical companies, or that its blood-testing devices were being used by the military, Schenk said.

Holmes’s attorney Kevin Downey, in his closing arguments to the jury, said there’s a “fundamental disconnect” in the government’s claim that she intentionally deceived investors about what her startup’s analyzers could do.

Downey told the jury that the government’s fixation on the shortcomings of early versions of the devices misses the point that Holmes was courting investors who were looking to hold onto shares for five or 10 years by telling them what she aspired to accomplish when the machines were fully developed.

“She believed she was building a technology that would change the world,” Downey said, adding that she’d sacrificed her youth, friends and family relationships to make Theranos successful. 

The government’s version of events is that Holmes was aware of “a thousand crimes hidden under the rocks of this company,” he said. The truth is Holmes didn’t sell a single share of Theranos stock, even as her company collapsed, and hung on until through the very end, he said. “She stayed. Why? Because she believed in this technology,” Downey said. “She stayed the whole time. She went down with this ship”

He also showed the jury a graph showing that Theranos’s stock price rose from 92 cents in 2006 to $17 in 2014. He argued that investors weren’t concerned about the company’s technology. Instead, all they needed to know was that Walgreens had agreed to put the machines in its stores. It meant “a big national company” had evaluated the technology and decided to partner with Theranos, he said. 

“It’s a statement that this technology company is going to be able to make its technology available,” Downey said.

The defense attorney then took on one of the government’s most damning claims at the trial: That Holmes lied by telling investors Theranos technology was adopted and used by the U.S. military. He took specific aim at tapes the government played at trial in which Holmes is describing the military’s adoption to an investor and, separately, to a journalist. 

Downey noted that Theranos did indeed have multiple military contracts and told the jury, “her words track the contract language,” Downey said.

“They are being told, I think accurately, what the state of the business is,” Downey said. “This was not a fiction that Ms. Holmes was making up in her conversation” or an “exaggeration.”

Downey made no mention of one of the most jolting revelations of the trial, when Holmes testified she was raped as a student at Stanford University and suffered years of verbal and sexual abuse from her former boyfriend, former Theranos President Ramesh “Sunny” Balwani. By Holmes’s account, the abuse lasted throughout the decade-long relationship with Balwani and had a profound if incalculable influence on her life. 

Schenk told the jury that the rape claim had no bearing on the criminal case. “You do not need to decide whether that abuse happened in order to reach a verdict,” he said. “The case is about false statements made to investors and false statements made to patients.” 

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Authors
By Joel Rosenblatt
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Tech

Big TechStreaming
Trump warns Netflix-Warner deal may pose antitrust ‘problem’
By Hadriana Lowenkron, Se Young Lee and BloombergDecember 7, 2025
7 hours ago
Big TechOpenAI
OpenAI goes from stock market savior to burden as AI risks mount
By Ryan Vlastelica and BloombergDecember 7, 2025
7 hours ago
AIData centers
HP’s chief commercial officer predicts the future will include AI-powered PCs that don’t share data in the cloud
By Nicholas GordonDecember 7, 2025
9 hours ago
Future of WorkJamie Dimon
Jamie Dimon says even though AI will eliminate some jobs ‘maybe one day we’ll be working less hard but having wonderful lives’
By Jason MaDecember 7, 2025
13 hours ago
CryptoCryptocurrency
So much of crypto is not even real—but that’s starting to change
By Pete Najarian and Joe BruzzesiDecember 7, 2025
18 hours ago
Elon Musk
Big TechSpaceX
SpaceX to offer insider shares at record-setting $800 billion valuation
By Edward Ludlow, Loren Grush, Lizette Chapman, Eric Johnson and BloombergDecember 6, 2025
1 day ago

Most Popular

placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
1 day ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
1 day ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
3 days ago
placeholder alt text
Politics
Supreme Court to reconsider a 90-year-old unanimous ruling that limits presidential power on removing heads of independent agencies
By Mark Sherman and The Associated PressDecember 7, 2025
15 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.